Renal Denervation Market Research Report: by Product (Symplicity, Vessix (V2), EnligHTN, Paradise, Iberis, Others), by Technology (Radiofrequency, Ultrasound, Micro-infusion, and Others), by End-user (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and Region - Forecast To 2030
ID: MRFR/MED/5249-HCR | February 2023 | Region: Global | 115 Pages
Speak to Analyst
Request a Free Sample
Renal Denervation Market
Renal denervation market is expected to rising from USD 200 million in 2017 to USD 11,488.51 million in 2030, at a solid CAGR of 38.60% over the forecast period
$11,488.51 million
38.60%
USA
2020-2030
Renal Denervation Market Overview:
Over the 2022-2030 projection periods, the renal denervation market is predicted to grow at a respectable CAGR of 38.60 percent, with the industry's value growing from USD 200 million in 2017 to USD 11.48 billion in 2030. The growing prevalence of hypertension throughout the world is driving the renal denervation market. According to the CDC, the prevalence of hypertension among persons aged 20 and up was close to 26% in 2000.
Over the next 10 years, the prevalence of hypertension is expected to rise by 5.2 percent, making it a major worry for the global healthcare industry. Developed nations have been aggressive in implementing efforts to combat and minimize the prevalence of hypertension among their populations, resulting in rising levels of hypertension. Renal denervation is a minimally invasive treatment for resistant hypertension. To lower sympathetic activity in the kidney and blood pressure, RF or ultrasonic ablation of nerves in the renal artery is used.
Major Key Players Competitive Analysis:Leading players in the renal denervation market include Boston Scientific, Medtronic, ReCor Medical, St. Jude Medical, Cardiosonic, Cordis, Kona Medical, Sound Intervention, and Terumo.The renal denervation market is hamstrung by challenging government regulations in regions such as the U.S. Medtronic recently announced the launch of a new placebo-controlled randomized clinical trial in an effort to get regulatory approval in the U.S., a major commercial market for high blood pressure remedies.Segmentation:The renal denervation market is segmented on the basis of product, technology, and end use.By product, the renal denervation market is segmented into Symplicity, Vessix (V2), EnligHTN, Paradise, Iberis, and others. Symplicity holds the largest market share in the renal denervation market at present and is likely to remain a leading contributor over the forecast period. However, Paradise is likely to be the fastest growing product segment in the renal denervation market over the forecast period.On the basis of technology, the renal denervation market is divided into radiofrequency, ultrasound, micro-infusion, and others. Radiofrequency is likely to be the fastest growing segment over the forecast period, eclipsing ultrasound, the largest market segment at present, in terms of growth rate.By end user, the renal denervation market is segmented into hospitals, clinics, ambulatory surgical centers, and others. Hospitals are the largest segment in the global renal denervation market, while ambulatory surgical centers are expected to exhibit the fastest growth over the forecast period.By region, the renal denervation market is segmented into North America, Europe, Asia Pacific (APAC), and Rest of the world. By Product
- Symplicity
- Vessix (V2)
- EnligHTN
- Paradise
- Iberis
- Others
By Technology
- Radiofrequency
- Ultrasound
- Micro-infusion
- Others
By End-user
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others
Report MethodologyAccuracy of the data has been maintained at all cost in the report. The report contains information gathered from primary interviews with the industry’s leading lights as well as information gathered from reliable secondary research. The research is carried out according to a domain-specific formula to ensure the accuracy of the data gathered. A comprehensive look at the market is provided through the report’s granular look at the market’s segmentation, and the use of a top-down and bottom-up approach supports this premiseRecent Development
Boston Scientific Corporation (Boston Scientific or 'the firm') is a maker of interventional medical equipment. Drug-eluting coronary stent systems, percutaneous coronary interventions, intravascular catheter-directed ultrasonography imaging catheters, fractional flow reserve, and systems and equipment utilized in coronary arteries and heart chambers are among the company's offerings. The company's products and services are available to clinics, outpatient facilities, hospitals, and medical offices all around the world. Boston Scientific is based in Marlborough, Massachusetts, in the United States.
The RADIANCE-II pivotal study of ReCor Medical's Paradise Ultrasound Renal Denervation (uRDN) System to treat hypertension has concluded subject enrollment. The Paradise uRDN System was created by the business as a minimally invasive treatment for treating hyperactive nerves leading to the kidney. The RADIANCE-II pivotal study is aimed to assess the platform's ability to treat uncontrolled hypertension in individuals using zero to two antihypertensive oral medicines.
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size |
|
| CAGR | 38.60% (2020-2030) |
| Base Year | 2019 |
| Forecast Period | 2020-2030 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Technology, and End use |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Boston Scientific, Medtronic, ReCor Medical, St. Jude Medical, Cardiosonic, Cordis, Kona Medical, Sound Intervention, and Terumo |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers |
|
